Feasibility of treating prehypertension with an angiotensin-receptor blocker.

By S. Julius, S. Nesbitt, Brent M. Egan, M. Weber, Eric L. Michelson, N. Kaciroti, Henry R. Black, Richard H. Grimm, F. Messerli, S. Oparil and 1 more. New England Journal of Medicine, 2006

905 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/63b697dfaceb7987ce12fe02134d50f39e852326

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Laurent
2. E. Schiffrin
3. S. Grundy
4. H. S. Boudier
5. B. K. Pedersen
6. B. Saltin

In Nutrition and Dietetics

1. S. Grundy

Citations in the corpus

• Subgroup Identification and Variable Selection from Randomized Clinical Trial Data. (2013, methodology): “47 4.1 P-values for TROPHY data . . . . . . . . . . . . . . . . . . . . .”
• The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, background): “It is true that two studies have shown that a few years’ administration of antihypertensive agents to individuals with high normal BP can delay transition to hypertension [285,286], but how far the benefit of this early intervention lasts—and whether it can also delay events and be cost-effective—re”
• The metabolic syndrome. (2003, positive): “Finally, the use of an ARB in individuals with prehypertension may prevent or postpone the development of stage I hypertension as shown in the Trial of Preventing Hypertension (TROPHY) study [88].”
• 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, neutral): “Behavioral therapies, including guided breathing, yoga, transcendental meditation, and biofeedback, lack strong evidence for their long-term BP-lowering effect (51, 57-61).”